Top news of July: Permanent makeup, FDA approvals, tattoos, more
Click Here to Manage Email Alerts
Healio has compiled July’s most-read news in dermatology.
The top articles include many of the FDA approvals that occurred last month as well as Q&As on the benefits of permanent makeup and the history, complications and risks associated with tattoos.
Q&A: Dermatologists can use power of permanent makeup to physically, mentally aid patients
In the top article of month, Healio spoke with Walter Liszewski, MD, FAAD, assistant professor of dermatology and preventative medicine at Northwestern Feinberg School of Medicine, about how permanent makeup can benefit patients with dermatological diseases, both physically and mentally. Read more.
FDA approves Xeomin as first neurotoxin for simultaneous treatment of facial lines
At the end of July, the FDA approved Xeomin (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines including severe glabellar frown lines, forehead lines and crow’s feet. Read more.
Q&A: On National Tattoo Day, dermatologist talks history, uses, risks of longtime art form
In honor of National Tattoo Day, celebrated every year on July 17, Healio spoke with Deborah S. Sarnoff, MD, FAAD, FACP, clinical professor in the department of dermatology at New York University, president of the Skin Cancer Foundation and a private practitioner in Manhattan and Long Island, about the history of tattoos, their applications and the complications that may arise from them. Read more.
FDA approves Zoryve for atopic dermatitis in adults, children
On July 9, the FDA approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older. Read more.
Early life nutrition could impact psoriasis risk
A higher risk for developing psoriasis was found in subjects who were fed formula as infants compared with those who were breastfed for at least the first 4 months of life, according to a Swedish study. Read more.
FDA grants regulatory clearance to XSense Cryoablation System in many indications
On July 1, IceCure Medical received marketing authorization from the FDA for its next-generation single probe cryoablation system for use across multiple specialties. Read more.
Collagen, vitamin C supplementation improves signs of aging in skin
Supplementation with a formulation comprised of collagen and vitamin C improved the signs of aging including dermis density, texture and wrinkles, according to a study. Read more.
Studies find benzoyl peroxide for acne has no increased risk for blood benzene, malignancy
A watchdog organization previously reported high levels of the carcinogen benzene in benzoyl peroxide products, but two recent studies found no increase in blood benzene levels or malignancy in patients using these products for acne. Healio spoke with John Barbieri, MD, MBA, assistant professor at Harvard Medical School and director of the advanced acne therapeutics clinic at Brigham and Women’s Hospital, who was an author on both studies. Read more.
FDA clears first fractional radiofrequency microneedling tool for soft tissue contraction
On July 17, the FDA cleared the first and only fractional radiofrequency microneedling technology for contraction of soft tissue. Read more.
Clascoterone linked to mild, reversible HPA axis suppression in patients with acne
Clascoterone cream 1% caused mild, reversible hypothalamic-pituitary-adrenal axis suppression under maximum-use exposure in patients with acne vulgaris, according to a study. Healio spoke with Adelaide A. Hebert, MD, chief of pediatric dermatology at McGovern School of Medicine and Children’s Memorial Hermann Hospital, about the results. Read more.